The UroLift System from Teleflex Inc. - minimally invasive relief for BPH patients
29.06.2026 - 07:23:24 | ad-hoc-news.de
Reviewed: ad hoc news Bestseller & Flagship desk. Edited and checked on 2026-06-29, 07:22. Details in the imprint.
The UroLift System from Teleflex Inc. sits on a small stainless-steel tray in the urologist's hand, a compact delivery device that looks more like a precision tool than a surgical weapon, and promises to ease the daily struggle of men with BPH in minutes.
How UroLift works
The UroLift System is an office-based, minimally invasive procedure that uses tiny permanent implants to lift and hold the enlarged prostate tissue away from the urethra, improving urine flow without cutting or removing tissue.The official UroLift physician page details the implant mechanism.
During the procedure, typically done under local or light anesthesia, the urologist advances a small cystoscope-like device through the urethra and deploys several implants, each creating a tension that opens the channel so patients can often feel a noticeably freer stream the same day.Teleflex has published data showing durability of results through five years.
Background on Teleflex Inc. shares
The UroLift System is one of Teleflex's key growth drivers in the urology portfolio and a recurring topic in the company’s investor communication.
What patients feel after
Many men report that the first trip to the bathroom after UroLift feels oddly quiet: no straining, less urgency, and a smoother stream, often without the need for a post-op catheter, which is a key selling point compared to traditional surgery.Patient-focused UroLift material highlights the short recovery and catheter-free approach.
Teleflex positions UroLift as a middle ground between chronic medication and more invasive procedures like transurethral resection of the prostate, aiming to preserve sexual function and minimize time away from work, so patients can return to daily routines within a few days.
Who stands behind UroLift
The UroLift System originated at Neotract, acquired by Teleflex in 2017, and today sits under the leadership of CEO Liam Kelly, who regularly singles out UroLift in earnings calls as a strategic pillar of the interventional urology franchise.Teleflex's acquisition announcement of Neotract outlines the rationale behind betting on UroLift.
In clinics, urologists such as Dr. Claus Roehrborn, an early investigator and vocal proponent of office-based BPH therapies, have helped shape the real-world profile of UroLift through trials that focus as much on quality-of-life metrics as on flow rates.
Benefits and trade-offs
Compared with medication, UroLift offers the prospect of a single procedure that reduces urinary symptoms without the ongoing burden of pills and potential systemic side effects, which many patients find both practical and mentally freeing.
However, UroLift is not suitable for every prostate anatomy, and outcomes can vary, with some patients needing additional implants or later procedures; Teleflex itself emphasizes careful patient selection and clear expectation-setting in its professional guidance.
Market and access
UroLift is cleared by the US FDA for the treatment of lower urinary tract symptoms due to BPH and is reimbursed by major US insurers, which has helped drive adoption, especially in high-volume urology practices across North America.
Outside the US, Teleflex has expanded UroLift into Europe and other markets through a mix of specialist distributors and direct sales teams, but availability can vary significantly, so patients typically start by asking local urologists rather than searching retail channels.
Teleflex and its shares
Teleflex has built a broad portfolio spanning vascular access, anesthesia, and surgical instruments, yet UroLift remains one of its most visible branded therapies in the consumer-facing urology space and a regular focus for growth commentary. Teleflex Inc. shares (ISIN US8793691069) trade on the New York Stock Exchange in US dollars.
Key facts on the UroLift System
- Product: UroLift System
- Manufacturer: Teleflex Incorporated
- Category: Flagship/Bestseller urology therapy
- Launch: Initial US launch after FDA clearance in 2013
- RRP / Price: Procedure pricing varies by provider and payer, typically billed through medical reimbursement rather than direct retail purchase
- Availability: Primarily through urology clinics and hospitals in the US, Europe and selected international markets
- Target group: Men with benign prostatic hyperplasia experiencing lower urinary tract symptoms
- Highlight / USP: Minimally invasive permanent implants that relieve BPH symptoms without cutting or removing prostate tissue and often without post-op catheterization
This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.
